Full history for every metric is available with a Kvantra account
Key financial summary
Financials in ZAR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | ZAR m | 15 | 32 | 40 | 41 | 40 | 90 | 90 |
| Operating profit | ZAR m | 27 | 27 | |||||
| Net profit | ZAR m | 131 | 53 | -32 | 183 | 44 | 19 | 19 |
| EPS reported | ZAR | 0.29 | 0.28 | |||||
| Operating cashflow per share | ZAR | -0.26 | -0.26 | |||||
| Capex per share | ZAR | 0.00 | 0.00 | |||||
| FCF per share | ZAR | -0.26 | -0.26 | |||||
| Free cash flow | ZAR m | -17 | -17 | |||||
| Net debt | ZAR m | -2 | -2 | |||||
| Book value equity | ZAR m | 1,097 | 1,097 | |||||
| Book value per share | ZAR | 16.95 | 16.95 | |||||
| Number of shares | m | 64.69 | 64.69 | |||||
| DPS (TTM paid) | ZAR | 0.00 | 0.00 |
Financial summary
Financials in ZAR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 7.24 | - | |||||
| P/B LTM | x | 0.12 | 0.10 | |||||
| P/S LTM | x | 1.52 | 1.26 | |||||
| P/FCF LTM | x | -8.23 | -6.82 | |||||
| EV/EBITDA LTM | x | 4.88 | 3.94 | |||||
| EV/Sales LTM | x | 1.52 | 1.23 | |||||
| Earnings Yield LTM | % | 13.81% | 16.50% | |||||
| FCF Yield | % | -12.15% | -14.66% | |||||
| Quality | ||||||||
| ROE | % | 1.69% | 1.69% | |||||
| ROIC | % | 2.14% | 2.14% | |||||
| Operating margin | % | 30.10% | 30.10% | |||||
| Gross margin | % | 92.71% | 92.71% | |||||
| FCF/Sales | % | -18.43% | -18.43% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | -57.35% | -57.35% | |||||
| Sales Growth YoY | % | +124.88% | +124.88% | |||||
| Net Income Growth YoY | % | -57.73% | -57.73% | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | -70.85% | -70.85% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.59 | -0.59 | |||||
| Net Debt/EBITDA | x | 0.02 | 0.02 | |||||
| EBIT/Net interest | x | 2.29 | 2.29 | |||||
| Net debt/market cap | % | -1.68% | -2.02% | |||||
| Net debt/Equity | x | -0.00 | -0.00 | |||||
| Gross debt/equity | x | 0.03 | 0.03 | |||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
RH Bophelo Limited primarily allocates its capital within the healthcare industry in South Africa. The company's investment strategy focuses on equity, quasi-equity, and other equity-linked instruments, targeting operational infrastructure across various sub-sectors. These include health insurance, private hospital facilities, pharmaceuticals, and the retail and distribution networks. The firm was established in 2016, with its headquarters located in Johannesburg, South Africa, and operates as a subsidiary of Public Investment Corporation SOC Limited.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
RH Bophelo Limited (RHB.JO)
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
RH Bophelo Limited primarily allocates its capital within the healthcare industry in South Africa. The company's investment strategy focuses on equity, quasi-equity, and other equity-linked instruments, targeting operational infrastructure across various sub-sectors. These include health insurance, private hospital facilities, pharmaceuticals, and the retail and distribution networks. The firm was established in 2016, with its headquarters located in Johannesburg, South Africa, and operates as a subsidiary of Public Investment Corporation SOC Limited.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free